Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA Sequencing of si-Contol treated M010817 and siSMAD7 treated M010817 human melanoma cell line

ABSTRACT: RNA Sequencing of si-Contol treated M010817 and siSMAD7 treated M010817 human melanoma cell line

PROVIDER: PRJNA451514 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7058280.fastq.gz	Fastqsanger.gz
	SRR7058281.fastq.gz	Fastqsanger.gz
	SRR7058282.fastq.gz	Fastqsanger.gz
	SRR7058277.fastq.gz	Fastqsanger.gz
	SRR7058278.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

RNA Sequencing of si-Contol treated M010817 and siSMAD7 treated M010817 human melanoma cell line

Project description:Purpose: Next-generation sequencing (NGS) has revolutionized systems-based analysis of cellular pathways. The goals of this study are to compare NGS-derived retinal transcriptome profiling (RNA-seq) to microarray and quantitative reverse transcription polymerase chain reaction (qRT–PCR) methods and to evaluate protocols for optimal high-throughput data analysis Methods: mRNA profiles of si-Contol treated M010817 and siSMAD7 treated M010817 human melanoma cell line were generated by deep sequencing, in triplicate, using Illumina HiSeq 2500. The sequence reads that passed quality filters were analyzed at the transcript isoform level with two methods: Burrows–Wheeler Aligner (BWA) followed by ANOVA (ANOVA) and TopHat followed by Cufflinks. qRT–PCR validation was performed using TaqMan and SYBR Green assays Conclusions: Our study represents the first detailed analysis of si-Contol treated M010817 and siSMAD7 treated M010817 human melanoma cell line transcriptomes, with biologic replicates, generated by RNA-seq technology. The optimized data analysis workflows reported here should provide a framework for comparative investigations of expression profiles. Our results show that NGS offers a comprehensive and more accurate quantitative and qualitative evaluation of mRNA content within a cell or tissue. We conclude that RNA-seq based transcriptome characterization would expedite genetic network analyses and permit the dissection of complex biologic functions.

2020-04-10 | GSE113472 | GEO

RNA sequencing for HUVECs treated with si-FLRT2

Project description:RNA sequencing for HUVECs treated with si-control or si-FLRT2

2022-01-22 | GSE179836 | GEO

Profiling melanoma cell line M14 treated with vemurafenib

Project description:Profiling melanoma cell line M14 treated with vemurafenib

| PRJNA556610 | ENA

RNA sequencing for HUVECs treated with si-FLRT2

Project description:RNA sequencing for HUVECs treated with si-FLRT2

| PRJNA745197 | ENA

RNA-seq analysis of A498 cell line treated with siSETD2 or si-NC

Project description:RNA-seq analysis of A498 cell line treated with siSETD2 or si-NC

| PRJNA551678 | ENA

Human WM35 melanoma cell line treated with ciclopirox and crizotinib

Project description:To generate drug signatures in human WM35 melanoma cell line. WM35 cell line was plated at 4 x 105 cells/mL overnight and treated with ciclopirox or crizotinib at 75% inhibitory concentrations (IC75, determined previously at 72h of treatment) or DMSO (vehicle) for 8h or 24h before harvest.

2018-01-01 | GSE59342 | GEO

Mouse melanoma cell line B16-F10 treated with G007-LK

Project description:Mouse melanoma cell line B16-F10 treated with G007-LK

| PRJEB33271 | ENA

Human WM35 melanoma cell line treated with trifluorothymidine(TFT) and lactimidomycin(LTM)

Project description:To generate drug signatures in human WM35 melanoma cell line. WM35 cell line was plated at 4 x 105 cells/mL overnight and treated with trifluridine or lactimidomycin at 75% inhibitory concentrations (IC75, determined previously at 72h of treatment) or DMSO (vehicle) for 8h or 24h before harvest.

2018-01-01 | GSE59341 | GEO

Effect of alisertib and navitoclax on gene expression in B16 melanoma tumors

Project description:To investigate how tumor cells respond to alisertib and navitoclax single agents and combonation therapy in vivo, mice with melanoma were treated with these agents or vehicle-contol. RNAseq was used to investigate gene expression in tumors

2022-10-26 | GSE212127 | GEO

Next Generation Sequencing of si-NC and si-circFAM120A Transcriptomes

Project description:Purpose: to find the potential down-stream target gene of circFAM120A Methods: mRNA profiles of decidualized human endometrial stromal cells (hESCs) after down-regulated FAM120A and control using siRNA were generated by NGS and compared by bioinformatics analysis Results: we sequenced 26414 mRNAs in hESCs between the si-NC and si-circFAM120A groups and identified 242 differentially expressed mRNAs, between which 161 were downregulated and 81 were up-regulated in si-circFAM120A group Conclusions: Our study represents the detailed analysis of decidualized hESCs transcriptomes between si-NC and si-circFAM120A groups.

2023-06-30 | GSE174495 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data